Download PDF
Geburtshilfe Frauenheilkd 2010; 70(8): 619-624
DOI: 10.1055/s-0030-1250168
Kongressbericht

© Georg Thieme Verlag KG Stuttgart · New York

ASCO 2010 – Erweiterung der Standards durch molekulare Therapien? Ein Kongressbericht der 46. Jahrestagung der American Society of Clinical Oncology, Chicago 4–8. 6. 2010

Conference Report on the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago June 4–8, 2010L. C. Hanker1 , K. Schwedler1 , E. Ruckhäberle1 , M. Kaufmann1
  • 1Klinik für Gynäkologie und Geburtshilfe der J. W. Goethe-Universität, Frankfurt
Further Information

Publication History

eingereicht 1.7.2010 revidiert 2.7.2010

akzeptiert 5.7.2010

Publication Date:
18 August 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Auf dem diesjährigen ASCO lag ein Schwerpunkt auf der operativen und strahlentherapeutischen Therapie des Mammakarzinoms. So konnten die finalen Ergebnisse der NSABP‐B‐32-Studie vorgestellt werden, die die Sicherheit der Wächterlymphknoten-Biopsie im Vergleich zur Axilladissektion bestätigte. Die überraschenden Resultate der ACOSOG-Z0011-Studie hingegen könnten Einfluss auf den Standard nehmen, da sie gegen eine routinemäßige Axilladissektion bei positivem Sentinellymphknoten sprechen. Ebenfalls konnte gezeigt werden, dass der alleinige immunhistochemische Nachweis von Mikrometastasen im Lymphknoten keine prognostische Relevanz hat. Eine neue Option der Strahlentherapie stellt zum einen die intraoperative Radiatio dar. Hier konnte die randomisierte TARGIT-Studie günstigere Nebenwirkungsraten bei vergleichbarer lokaler Kontrolle nach 24 Monaten hervorbringen. Zum anderen zeigte sich in der CACGB-9343-Studie bei Patientinnen über 70 Jahre, dass nur ein sehr geringer Benefit der postoperativen Bestrahlung nach Lumpektomie besteht. Die gepoolte Analyse der BRITS- und DESTINY-Studien konnte belegen, dass eine hohe therapierelevante Rezeptordiskordanz in der metastasierten Situation vorkommt. In dieser Situation konnte der Multityrosinkinaseinhibitor Sunitinib in Kombination mit Capecitabin oder Docetaxel nicht überzeugen. Bevacizumab bestätigt hingegen seinen Effekt auf das PFS in einer Metaanalyse. Die neueren molekularen Therapien wie T‐DM1 und die PARP-Inhibitoren müssen intensiver untersucht werden. Bei den gynäkologischen Karzinomen zeigt sich nun auch ein Trend zu zielgerichteten Therapien. Die Erhaltungstherapie mit Bevacizumab in der Primärtherapie des Ovarialkarzinoms zeigte einen signifikanten Vorteil gegenüber der alleinigen Standardtherapie. Des Weiteren können die Kombinationen aus Carboplatin und PEG-liposomalem Doxorubicin oder Gemcitabin aufgrund der Studiendaten in bestimmten Fällen Alternativregime in der Primärtherapie darstellen. In der Rezidivsituation werden vielversprechende molekulare Substanzen wie PARP-Inhibitoren, „Peptibodies“ oder Arzneimittelkonjugate geprüft. In der Therapie des Zervix- und Endometriumkarzinoms waren neue sequenzielle Radiochemotherapieregime sowie antiangiogenetische Substanzen vielversprechend.

Schlüsselwörter

ASCO - Mammakarzinom - Ovarialkarzinom - Zervixkarzinom - Endometriumkarzinom

Literatur

  • 1 Krag D N, Anderson S J, Julian T B et al. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 505
    PubMedGoogle Scholar
  • 2 Giuliano A E, McCall L M, Beitsch P D et al. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1–2 N0 M0 breast cancer who have a positive sentinel node.  J Clin Oncol. 2010;  28 June 20 (Suppl.), CRA 506
    PubMedGoogle Scholar
  • 3 Cote R, Giuliano A E, Hawes D et al. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), CRA 504
    PubMedGoogle Scholar
  • 4 Hughes K S, Schnaper L A, Cirrincione C et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 507
    PubMedGoogle Scholar
  • 5 Baum M, Joseph D J, Tobias J S et al. Safety and efficacy of targeted intraoperative radiotherapy (TARGIT) for early breast cancer: First report of a randomized controlled trial at 10-years maximum follow-up.  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 517
    PubMedGoogle Scholar
  • 6 Ellis M J, Buzdar A, Unzeitig G W et al. ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 513
    PubMedGoogle Scholar
  • 7 Carpenter R, Doughty J C, Cordiner C et al. A multicenter study to determine the optimum duration of neoadjuvant letrozole on tumor regression to permit breast-conserving surgery: Final analyses.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 670
    PubMedGoogle Scholar
  • 8 von Minckwitz G, Untch M, Nueesch E et al. Impact of treatment characteristics on response of different breast cancer subtypes: pooled multilayer analysis of the German neoadjuvant chemotherapy trials.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 501
    PubMedGoogle Scholar
  • 9 Pfeiler G, Königsberg R, Singer C F et al. Impact of body mass index (BMI) on endocrine therapy in premenopausal breast cancer patients: an analysis of the ABCSG-12 trial.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 512
    PubMedGoogle Scholar
  • 10 Dezentje V O, Van Schaik R H, Vletter-Bogaartz J M et al. Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 501
    PubMedGoogle Scholar
  • 11 Amir E, Clemons M, Freedman O C et al. Tissue confirmation of disease recurrence in patients with breast cancer: pooled analysis of two large prospective studies.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 1007
    PubMedGoogle Scholar
  • 12 O'Shaughnessy J, Miles D, Gray R J et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 1005
    PubMedGoogle Scholar
  • 13 Twelves C, Loesch D, Blum J L et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane.  J Clin Oncol. 2010;  28 June 20 (Suppl.), CRA 1004
    PubMedGoogle Scholar
  • 14 Crown J, Dieras V, Staroslawska E et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 1011
    PubMedGoogle Scholar
  • 15 Bergh J, Greil R, Voytko N et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 1010
    PubMedGoogle Scholar
  • 16 Dalenc F, Campone M, Hupperets P et al. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 1013
    PubMedGoogle Scholar
  • 17 Miller K, Gianni L, Andre F et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 1012
    PubMedGoogle Scholar
  • 18 O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: results of a randomized phase II-trial.  J Clin Oncol. 2009;  27 18 s (Suppl.), Abstr. 3
    CrossrefPubMedGoogle Scholar
  • 19 Gelmon K A, Hirte H W, Robidoux A et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr 3020
    PubMedGoogle Scholar
  • 20 Dent R A, Lindeman G J, Clemons M et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 1018
    PubMedGoogle Scholar
  • 21 Isakoff S J, Overmoyer B, Tung N M et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 1019
    PubMedGoogle Scholar
  • 22 Lu K H, Skates S, Bevers T B et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA).  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5030
    PubMedGoogle Scholar
  • 23 Burger R A, Brady M F, Bookman M A et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study.  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 1
    PubMedGoogle Scholar
  • 24 Teneriello M G, Gordon A N, Lim P et al. Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 5008
    PubMedGoogle Scholar
  • 25 Pignata S, Scambia G, Savarese A et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Final analysis of the Mito-2 randomized multicenter trial.  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 5033
    PubMedGoogle Scholar
  • 26 Meier W, Lichtenegger W, Marth C et al. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): a planed 200-pt interim safety analysis of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG Intergroup Study (HECTOR).  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5071
    PubMedGoogle Scholar
  • 27 Naumann R W, Symanowski J T, Ghamande S A et al. PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), LBA 5012b
    PubMedGoogle Scholar
  • 28 Karlan B Y, Oza A M, Hansen V L et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5000
    PubMedGoogle Scholar
  • 29 Gelmon K A, Hirte H W, Robidoux A et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 3020
    PubMedGoogle Scholar
  • 30 Konstantinopoulos P, Spentzos D, Karlan B et al. A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5004
    PubMedGoogle Scholar
  • 31 Dueñas-González A, Zarba J J, Alcedo J C et al. A randomized phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix.  J Clin Oncol. 2009;  27 June 20 (Suppl.), CRA 5507
    PubMedGoogle Scholar
  • 32 Sehouli J, Blohmer J U, Kuemmel S et al. Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup Study.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5005
    PubMedGoogle Scholar
  • 33 Schefter T E, Moughan J, Kwon J S et al. RTOG 0417: A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5006
    PubMedGoogle Scholar
  • 34 Geller M A, Ivy J, Ghebre R et al. A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5029
    PubMedGoogle Scholar
  • 35 Narayan K, Rischin D, Quinn M et al. Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5028
    PubMedGoogle Scholar
  • 36 Bevis K S, Kilgore L C, Alvarez R D et al. Combination therapy with paclitaxel, carboplatin, and megesterol acetate for advanced-stage and recurrent endometrial carcinoma: A phase II study.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 5093
    PubMedGoogle Scholar
  • 37 Locatelli M A, Curigliano G, Fumagalli L et al. Should liver metastases of breast cancer be biopsied to improve treatment choice.  J Clin Oncol. 2010;  28 June 20 (Suppl.), CRA1008
    PubMedGoogle Scholar
  • 38 Karlsson E, Lindström L S, Wilking U et al. Discordance in hormone receptor status in breast cancer during tumor progression.  J Clin Oncol. 2010;  28 June 20 (Suppl.), Abstr. 1009
    PubMedGoogle Scholar

Dr. med. Lars Christian Hanker

Klinik für Gynäkologie und Geburtshilfe
J. W. Goethe-Universität

Theodor-Stern-Kai 7

60590 Frankfurt am Main

Email: hanker@med.uni-frankfurt.de

      >